Mode of action of trabedersen (AP12009) in Cancer Treatment

Malignant brain tumors (high-grade glioma), pancreatic cancer and malignant melanoma are among the most aggressive tumors known. Antisense Pharma is vigorously testing its product trabedersen (AP 12009) in different clinical studies with the aim to meet the unmet medical need for effective and innovative approaches to treat these cancers. Trabedersen downregulates the generation of one of the most important tumor-promoting factors - TGF-beta2 (TGF-β2) - at the molecular level. With its proangiogenic and promigratory effects, TGF-β2 plays a pivotal role in explosive tumor progression and the aggressive spread of tumor cells throughout the body (metastazation). In addition, tumor-derived TGF-β2 overexpression builds up a protective shield around the tumor. This shield results in an inactivation of immune cells and allows the tumor to escape the bodys immune surveillance. The tumor cells can spread unhindered throughout the body. The antisense drug trabedersen blocks the translation of the TGF-β2 mRNA and thus downregulates its synthesis, destroying the protective shield around the tumor. Further tumor growth is consequently inhibited and the bodys own immune system is reactivated, enabling the immune cells to combat the cancer cells.

Category:

Science & Technology

Tags:

• glioblastoma
• brain tumor
• glioma
• gbm
• trabedersen
• AP12009
• clinical trials
• recurrent
• or
• refractory
• anaplastic
• astrocytoma
• SAPPHIRE study

[MrSymposier]

It looks like trabedersen will be a great product against Cancer, giving our body the opportunity to recognize malignant cells, and with this our bodys immune system can work and get rid of them. Other interesting videos on Cancer and its treatment are available at Symposier Site (only for Physicians and Medical Experts), visit it.